Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 19 - Drugs for skeletal disorders
Patents for A61P 19 - Drugs for skeletal disorders (81,981)
10/2010
10/27/2010CN101869676A Medicinal liquor for treating cold and dampness
10/27/2010CN101869673A External patch preparation for treating cervical spondylosis and preparation method thereof
10/27/2010CN101869672A Moxibustion liquid and preparation process thereof
10/27/2010CN101869671A Paste for waist, leg, shoulder and neck
10/27/2010CN101869670A Anti-gout composition, preparation method and application thereof in preparation of anti-gout drugs
10/27/2010CN101869637A Medicament for treating rheumatism arthritis and preparation method thereof
10/27/2010CN101869624A External Chinese medicinal liquor for treating gout, acute coronary insufficiency, hypertension, chiral and pedal numbness and stremma
10/27/2010CN101869601A External veterinary medicament
10/27/2010CN101288728B Plaster for treating rheumatism, rheumatoid, a variety of hyperosteogenys
10/27/2010CN101209171B Pillow containing tea, carbon and Chinese herbal medicine composite granules and preparation method thereof
10/27/2010CN101156872B Compound recipe bone-peptide preparation
10/27/2010CN101102773B Aminopyrazine analogs for treating glaucoma and other RHO kinase-mediated diseases
10/27/2010CN101040889B Traditional Chinese medicinal prepns. for treating osteoporosis
10/26/2010USRE41895 Epothilone derivatives
10/26/2010USRE41893 Epothilone derivatives
10/26/2010US7820818 Inhibitors of cathepsin K; inflammation, rheumatoid arthritis, osteoarthritis, osteoporosis and tumors; 4-Cyclopentylamino-5-(4-phenyl-but-1-ynyl)-pyrimidine-2-carbonitrile; 5-[3-(3,4-Dihydro-1H-isoquinolin-2-yl)-prop-1-ynyl]-4-(2,2-dimethyl-propylamino)-pyrimidine-2-carbonitrile
10/26/2010US7820814 Inhibitors of kinases
10/26/2010US7820722 Comprises a multi-carbon backbone having an at least partially neutralized carboxy or sulfonic functional group and also one or more side chains that have one or more carbon atoms and, optionally, one or more functional groups.
10/26/2010US7820717 4-Chloro-2-phenylsulfanyl-phenyl)-4-isopropoxy-benzenesulfonamide; inflammatory bowl disease such as Crohn's disease or Colitis
10/26/2010US7820697 1-Oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline; treatment of cancers, rheumatoid arthritis, inflammatory bowel disease, muscular dystrophy, Crohn's disease and viral disease
10/26/2010US7820687 inflammatory diseases such as asthma, Alzheimer's disease, atherosclerosis, diabetes, autoimmune diseases, tumor metastasis and myocardial ischemia; improved bioavailability; 2-(2-(diethylamino)-5-(N-isopropylmethylsulfonamido)pyrimidin-4-ylamino)-3-(4-(pyrrolidine-1-carbonyloxy)phenyl)propanoic acid
10/26/2010US7820400 Tumor-associated marker
10/26/2010US7820197 Using bisphosphonic acid compound; mixture with solubilizer; permeability through skin
10/26/2010US7820178 VEGF isoforms and their use as anti-angiogenic, anti-vasodilatory, anti-permeability and anti-proliferative agents
10/26/2010US7820170 monoclonal antibody exhibit antagonist activity of the anti-CD40 antibody; antiproliferative agents; controlling cell differentiation; anticarcinogenic agents; Hodgkin's disease, leukemias
10/26/2010US7820161 Treatment of autoimmune diseases
10/26/2010CA2449192C Novel nitriles useful as reversible inhibitors of cysteine proteases
10/26/2010CA2434608C Promoting cell regeneration and/or cell differentiation with non-metabolizable sugar and a polymeric absorbent
10/26/2010CA2410201C Zoledronic acid or salts thereof for use in the treatment of conditions of abnormally increased bone turnover
10/26/2010CA2409221C Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compounds
10/26/2010CA2326501C Binding molecules derived from immunoglobulins which do not trigger complement mediated lysis
10/26/2010CA2293436C Imidazolyl-cyclic acetals as tnf inhibitors
10/26/2010CA2163111C Process for the preparation of an oral solid dosage form containing diclofenac
10/26/2010CA2133323C Self-assembling polynucleotide delivery system
10/21/2010WO2010120817A2 Nanochanneled device and related methods
10/21/2010WO2010120374A2 Peptides targeting tnf family receptors and antagonizing tnf action, compositions, methods and uses thereof
10/21/2010WO2010120332A1 Agents and methods to stimulate bone healing
10/21/2010WO2010120253A1 Thiocolchicoside and non-steroidal anti-inflammatory drug combinations
10/21/2010WO2010119875A1 Fused pyrrolopyridine derivative
10/21/2010WO2010118675A1 New use of neferine
10/21/2010WO2010076813A4 Thienopyridines as pharmacologically active agents
10/21/2010WO2010056044A3 Novel compound acting as a vanilloid receptor antagonist, isomer or pharmaceutically acceptable salt thereof, and pharmaceutical composition containing same
10/21/2010WO2010022177A3 Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use
10/21/2010US20100267936 PROCESS FOR CORRECTION OF A DISULFIDE MISFOLD IN Fc MOLECULES
10/21/2010US20100267822 Aurones as estrogen receptor modulators and their use in sex hormone dependent diseases
10/21/2010US20100267793 Method of treatment using n3 alkylated benzimidazole derivatives as mek inhibitors
10/21/2010US20100267784 Novel 4,5-dihydroisoxazoles with estrogenic activity
10/21/2010US20100267764 8-Aza-Bicyclo[3.2.1]Octane Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors
10/21/2010US20100267759 INHIBITORS OF Akt ACTIVITY
10/21/2010US20100267754 Integrin expression inhibitor
10/21/2010US20100267750 Methods and compositions for treating pain
10/21/2010US20100267738 Novel amide and amidine derivatives and uses thereof
10/21/2010US20100267721 Heterocyclic H3 Antagonists
10/21/2010US20100267720 Crystalline Forms of 2-Hydroxy-3- [5- (Morpholin- 4- Ylmethyl) Pyridin-2-YL] IH- Indole- 5 -Carbonitrile Citrate
10/21/2010US20100267717 Novel Heterocyclic NF-kB Inhibitors
10/21/2010US20100267710 N3 alkylated benzimidazole derivatives as mek inhibitors
10/21/2010US20100267700 Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient
10/21/2010US20100267689 4-azetidinyl-1-phenyl-cyclohexane antagonists of ccr2
10/21/2010US20100267671 Compositions and methods for apoptosis modulators
10/21/2010US20100267668 4-azetidinyl-1-heteroatom linked-cyclohexane antagonists of ccr2
10/21/2010US20100267651 T cell antigen receptor peptides
10/21/2010US20100267641 Prognostic tests for development of dermal stretch marks and implications for the preventative treatment thereof
10/21/2010US20100267639 Treatment of osteoarthritis
10/21/2010US20100267633 N-(4-Oxo-3,4-Dihydroquinazolin-2Yl) Butanamides as Androgen Receptor Modulators
10/21/2010US20100267626 Methods and compositions for measuring wnt activation and for treating wnt-related cancers
10/21/2010US20100267620 Methods for slowing senescence and treating and preventing diseases associated with senescence
10/21/2010US20100267612 Sustained release composition containing sdf-1
10/21/2010US20100267610 Polypeptide comprising a knottin protein moiety
10/21/2010US20100267140 Soluble inhibitors of vascular endothelial growth factor and use thereof
10/21/2010US20100266698 Use of insulin for the treatment of cartilaginous disorders
10/21/2010US20100266691 Agents and Methods to Stimulate Bone Healing
10/21/2010US20100266670 Transdermally absorptive preparation
10/21/2010US20100266661 Osteogenic implants with combined implant materials and methods for same
10/21/2010US20100266658 Osteogenic Implants with Combined Implant Materials and Methods for Same
10/21/2010US20100266657 Preformed drug-eluting device to be affixed to an anterior spinal plate
10/21/2010US20100266644 Methods and compositions for administration of iron
10/21/2010US20100266613 Anti-tnf-alpha antibodies and their uses
10/21/2010US20100266612 Bmp-alk3 antagonists and uses for promoting bone growth
10/21/2010US20100266602 Method for Diagnosing Rheumatoid Arthritis via Assaying Myofibroblast-Like Synoviocytes for Fibroblast Activation Protein
10/21/2010US20100266594 Il-9 in fibrotic and inflammatory disease
10/21/2010US20100266579 Treatment of inflammatory diseases
10/21/2010US20100266561 Recovery of Tissue Function Following Administration of B Cells to Injured Tissue
10/21/2010US20100266557 Novel peptide-based scaffolds for cartilage regeneration and methods for their use
10/21/2010US20100266551 Adeno-associated viral vectors for the expression of dysferlin
10/21/2010US20100266550 Mammalian milk microorganisms, compositions containing them and their use for the treatment of mastitis
10/21/2010US20100266535 Compounds Having CRTH2 Antagonist Activity
10/21/2010US20100266531 Il-17 binding proteins
10/21/2010US20100266490 Metalloproteinase Binding Proteins
10/21/2010CA2758542A1 Peptides targeting tnf family receptors and antagonizing tnf action, compositions, methods and uses thereof
10/21/2010CA2758359A1 Fused pyrrolopyridine derivative
10/20/2010EP2241315A1 Pharmaceutical composition, use of 2-iminopyrrolidine derivative for production of pharmaceutical composition, and kit for treatment or amelioration of heart diseases
10/20/2010EP2240515A1 Antigen-binding polypeptides against cartilage degeneration
10/20/2010EP2240501A1 Hydroxy-bisphosphonic acid derivatives as vector for targeting bone tissue
10/20/2010EP2240491A2 Compounds
10/20/2010EP2240480A2 Derivatives of 2-heteroaroyl-imidazol(1,2-a)pyridine,preparation thereof and therapeutic application thereof
10/20/2010EP2240463A2 2-methylene-(20s,25r)-19,26-dinor-vitamin d analogs
10/20/2010EP2240452A1 Certain chemical entities, compositions and methods
10/20/2010EP2240451A1 Certain chemical entities, compositions and methods
10/20/2010EP2240448A1 Lactam inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
10/20/2010EP2240440A2 2-methylene-(20s,25s)-19,26-dinor-vitamin d analogs
1 ... 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 ... 820